FIG. 1

Study Flow Diagram




FIG. 2

Exacerbation Rate by Blood Eosinophil Count

EOS		Interim Analysis				Stage I Analysis			
	Treatment Group	N	Rate	Reduction	*p*-value	N	Rate	Reduction	*p*-value
<300	Placebo	139	0.48			139	0.49		
	2mg	16	0.25	47%	---	16	0.21	57%	---
	20mg	11	0.75	---	---	11	0.82	---	---
	100mg	124	0.40	18%	0.481	124	0.42	16%	0.479
≥ 300	Placebo	83	0.65			83	0.68		
	2mg	65	0.66	1%	0.987	65	0.75	---	0.822
	20mg	70	0.24	63%	0.011	70	0.30	57%	0.014
	100mg	97	0.38	41%	0.073	97	0.38	43%	0.049

FIG. 3

Exacerbation Rate by Baseline ICS Status

ICS		Interim Analysis				Stage I Analysis			
	Treatment Group	N	Rate	Reduction	*p*-value	N	Rate	Reduction	*p*-value
Medium	Placebo	122	0.52			122	0.52		
	2mg	41	0.39	25%	0.473	39*	0.42	19%	0.578
	20mg	39	0.24	53%	0.125	39	0.28	46%	0.169
	100mg	117	0.30	42%	0.064	117	0.33	37%	0.100
High	Placebo	100	0.57			100	0.62		
	2mg	40	0.80	---	0.378	42*	0.85	---	0.326
	20mg	42	0.39	33%	0.370	42	0.46	25%	0.436
	100mg	105	0.49	14%	0.598	105	0.48	22%	0.331

*: Additional baseline ICS information was added after interim for two subjects.

FIG. 4

Exacerbation Rate by Blood Eosinophil Count and Baseline ICS Status

ICS			Interim Analysis				Stage I Analysis			
	Treatment Group	N	Rate	Reduction	*p*-value	N	Rate	Reduction	*p*-value
ICS=Medium EOS<300	Placebo	79	0.51			79	0.51		
	2mg	9	0.47	9%	---	7	0.49	4%	---
	20mg	4	0.85	---	---	4	1.00	---	---
	100mg	63	0.29	44%	0.167	63	0.33	37%	0.233
ICS=High EOS<300	Placebo	60	0.43			60	0.47		
	2mg	7	0.00	100%	---	9	0.00	100%	---
	20mg	7	0.68	---	---	7	0.71	---	---
	100mg	61	0.51	---	0.682	61	0.51	---	0.795

FIG. 5

Exacerbation Rate by Blood Eosinophil Count and Baseline ICS Status

ICS		Interim Analysis				Stage I Analysis			
	Treatment Group	N	Rate	Reduction	*p*-value	N	Rate	Reduction	*p*-value
ICS=Medium EOS ≥ 300	Placebo	43	0.53			43	0.52		
	2mg	32	0.37	29%	0.475	32	0.41	22%	0.583
	20mg	35	0.17	67%	0.039	35	0.19	64%	0.044
	100mg	54	0.31	41%	0.216	54	0.32	38%	0.264
ICS=High EOS ≥ 300	Placebo	40	0.80			40	0.86		
	2mg	33	0.97	---	0.668	33	1.07	---	0.566
	20mg	35	0.32	60%	0.102	35	0.41	52%	0.118
	100mg	43	0.47	42%	0.201	43	0.46	46%	0.102

FIG. 6



Annual Exacerbation Rate
xx% is % reduction
PLACEBO
Benralizumab 2 MG
Benralizumab 20 MG
Benralizumab 100 MG
Annual Exacerbation Rate (exac/yr)
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Baseline Rate = 0.65/yr
N=83
N=65
63% N=70
41% N=97
>=300 Cells/ul
p= .011; .073
N=139
N=16
N=11
18% N=124
<300 Cells/ul

FIG. 7A

Exacerbations by Baseline EOS Count


EOS Counts Cut -off	Treatment Group	N	Exacerbation Rate Ratio (90% CI)	Rate Reduction (%)	*p*-value
≥150	Placebo**	158			
	2 mg	76	1.23 (0.77, 1.97)		0.475
	20mg	78	0.65 (0.38, 1.14)	35	0.206
	100mg**	171	0.63 (0.42, 0.94)	37	0.056
<150	Placebo	64			
	2 mg	5			
	20mg	3			
	100mg	50	0.97 (0.53 1.80)	3	0.941
≥200	Placebo	139			
	2 mg	75	1.24 (0.77, 2.01		0.457
	20mg	78	0.67 (0.39, 1.15)	33	0.224
	100mg	151	0.67 (0.44, 1.01)	33	0.110
<200	Placebo	83			
	2 mg	6			
	20mg	3			
	100mg	70	0.82 (0.46, 1.45)	18	0.565

FIG. 7B

Exacerbations by Baseline EOS Count

EOS Counts Cut -off	Treatment Group	N	Exacerbation Rate Ratio (90% CI)	Rate Reduction (%)	*p*-value
≥300	Placebo**	83			
	2 mg	65	0.99 (0.59, 1.68)	1	0.987
	20mg	70	0.37 (0.19, 0.70)	63	0.011
	100mg**	97	0.59 (0.36, 0.96)	41	0.073
<300	Placebo	139			
	2 mg	16	0.53 (0.14, 1.95)		0.423
	20mg	11	1.62 (0.65, 4.00)		0.385
	100mg	124	0.82 (0.51, 4.31)	18	0.481
≥400	Placebo	52			
	2 mg	50	0.90 (0.51, 1.60)	10	0.765
	20mg	53	0.36 (0.17, 0.78)	64	0.028
	100mg	58	0.36 (0.18, 0.72)	64	0.015
<400	Placebo	170			
	2 mg	31	1.17 (0.57, 2.39)		0.721
	20mg	28	0.92 (0.44, 1.93)	8	0.852
	100mg	163	0.87 (0.59, 1.29)	13	0.566

FIG. 8


Eosinophil Depletion in Patients with at least 300 eosinophils/µl
EOS (10³/ul)
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
0
4
8
12
16
20
24
Week
Benralizumab 100 MG
Benralizumab 2 MG
Benralizumab 20 MG
PLACEBO